WELCOME TO THE FATATIS LABORATORY
The vast majority of patients with advanced cancers of the prostate and breast eventually succumb to metastatic disease. Our laboratory is focused on understanding the cellular and molecular factors implicated in metastasis and identifying novel and effective therapeutic targets to decelerate or arrest the emergence and progression of metastatic tumors.
DiNatale A, Worrede A, Iqbal W, Marchioli M, Toth A, Sjöström M, Zhu X, Corey E, Feng FY, Zhou W and Fatatis A. IL-1β expression driven by androgen receptor absence or inactivation promotes prostate cancer bone metastasis. Cancer Research Communication 12:1545-1557 (2022).
DiNatale A, Castelli MS, Nash B, Meucci O, Fatatis A. Regulation of tumor and metastasis Initiation by chemokine receptors. Journal of Cancer (2022)
DiNatale A, Kaur R, Qian C, Zhang J, Marchioli M, Ipe D, Castelli M, McNair CM, Kumar G, Meucci O, Fatatis A. Subsets of cancer cells expressing CX3CR1 are endowed with metastasis-initiating properties and resistance to therapy. Oncogene (2022)